知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

76 records (took 0.031 seconds)

    Compressive Raman classification of cells using a neural network for optical filter design and cell classification
    1.
    发明公开
    Compressive Raman classification of cells using a neural network for optical filter design and cell classification 审中-公开

    公开(公告)号：US20240302283A1

    公开(公告)日：2024-09-12

    申请号：US18119621

    申请日：2023-03-09

    Applicant: Universiteit Leiden

    Inventor： Stefan Semrau

    IPC: G01N21/65 ,  G02B26/08 ,  G06N3/067

    CPC classification number: G01N21/65 ,  G02B26/0833 ,  G06N3/0675 ,  G01N2201/06113

    Abstract: A method for cell classification performs a compressive Raman measurement of a cell sample that involves frequency filtering the dispersed optical signal by a tunable optical filter whose frequency response is defined by weights that were derived from trained weights of a first hidden layer of a neural network trained on Raman spectra of cells and corresponding labels. The frequency filtered signals are detected by an optical detector to produce a compressive Raman measurement. Multiple compressive Raman measurements are then input to a prediction neural network to predict a label of the cell sample. The prediction neural network is the same as the trained neural network except without the input layer and the weights of the first hidden layer.

    Apparatuses for and methods of processing cells and related structures
    5.
    发明授权
    Apparatuses for and methods of processing cells and related structures 有权

    公开(公告)号：US10900008B2

    公开(公告)日：2021-01-26

    申请号：US16571552

    申请日：2019-09-16

    Applicant: UNIVERSITEIT LEIDEN

    Inventor： Paul Vulto ,  Sebastiaan Johannes Trietsch ,  Heiko Jan van der Linden ,  Adrianus Theodoras Joore ,  Thomas Hankemeier

    IPC: C12M1/00 ,  B01F13/00 ,  B01L3/00 ,  C12M3/06 ,  C12M1/42

    Abstract: Apparatus for processing life-based organic particles, including particles selected from the list comprising cells, cellular spheroids, tissues, eukaryotes, micro-organisms, organs or embryos, comprises a hollow volume (10) that (a) is internally divided into at least first (14), second (16) and third (17) sub-volumes by at least two phaseguides (12, 13) formed inside the volume and (b) includes parts that are relatively upstream and relatively downstream when judged with reference to the movement of a meniscus or a bulk liquid in the volume (10). The apparatus includes at least first, second and third fluid conduits (19, 21, 22) connected to permit fluid communication between the upstream exterior of the volume (10) and a respective said sub-volume (14, 16, 17); and at least one further conduit (24) connected to permit fluid communication between the downstream exterior of the volume (10) and a said sub-volume. The first sub-volume (14) contains one or more life-based particles supported in or by a gel or gel-like substance; and the second sub-volume (16) communicates with the first sub-volume so as to permit transport of substances between the first and second sub-volumes (14, 16) and contains at least one gel or gel-like substance.

    N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
    6.
    发明授权
    N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase 有权

    公开(公告)号：US10590082B2

    公开(公告)日：2020-03-17

    申请号：US16241705

    申请日：2019-01-07

    Applicant: Academisch Medisch Centrum ,  Universiteit Leiden

    Inventor： Herman Steven Overkleeft ,  Stan Van Boeckel ,  Johannes Maria Franciscus Gerardus Aerts ,  Amar Ghisaidoobe ,  Richard Van Den Berg

    IPC: A61K31/445 ,  A61K31/4545 ,  A61P3/00 ,  A61P25/16 ,  A61P9/10 ,  C07D211/40 ,  C07D211/46

    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

    N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE
    8.
    发明申请
    N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE 审中-公开

    公开(公告)号：US20190144388A1

    公开(公告)日：2019-05-16

    申请号：US16241705

    申请日：2019-01-07

    Applicant: Academisch Medisch Centrum ,  Universiteit Leiden

    Inventor： Herman Steven OVERKLEEFT ,  Stan VAN BOECKEL ,  Johannes Maria Franciscus Gerardus AERTS ,  Amar GHISAIDOOBE ,  Richard VAN DEN BERG

    IPC: C07D211/40 ,  C07D211/46 ,  A61P3/00

    CPC classification number: C07D211/40 ,  A61P3/00 ,  C07D211/46

    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

    N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
    9.
    发明授权
    N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase 有权

    公开(公告)号：US10189784B2

    公开(公告)日：2019-01-29

    申请号：US15129815

    申请日：2015-03-23

    Applicant: ACADEMISCH MEDISCH CENTRUM ,  UNIVERSITEIT LEIDEN

    Inventor： Herman Steven Overkleeft ,  Stan Van Boeckel ,  Johannes Maria Franciscus Gerardus Aerts ,  Amar Ghisaidoobe ,  Richard Van Den Berg

    IPC: C07D211/14 ,  C07D401/12 ,  C07D405/12 ,  C07D211/40

    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

Patent Agency Ranking